Literature DB >> 15153326

Cost-effectiveness of a community-based screening programme for chronic atrial fibrillation in Japan.

K Maeda1, T Shimbo, T Fukui.   

Abstract

OBJECTIVES: To examine the cost-effectiveness of a community-based screening programme for chronic atrial fibrillation (AF) in Japan.
METHODS: Using a computer model of a Markov process, the cost-effectiveness of an annual ECG screening programme and an annual pulse palpation screening programme for arrhythmia were compared with no screening. A hypothetical Japanese population of 65 year old individuals was followed until 85 years of age. We assumed that individuals with irregular beats on palpation were worked up by ECG and that ECG was perfect in detecting AF, whereas palpation was not. It was also assumed that patients diagnosed with AF received anticoagulant therapy, that some AF patients developed ischaemic stroke, and that some on anticoagulant therapy developed intracranial or gastrointestinal haemorrhage. Costs, efficacy of anticoagulation, utility of health status, and clinical variables were estimated from the literature. Outcomes were expressed as US dollars per quality-adjusted life-year (QALY).
RESULTS: Both annual ECG screening programme and annual palpation screening programme were more costly and at the same time more effective compared with no screening, with their incremental cost-effectiveness ratios approximately US$8000 per QALY in males and US$10,000 per QALY in females. Sensitivity analyses showed high sensitivity of cost-effectiveness ratios to the incidence of ischaemic stroke and anticoagulants prescription rate. Two annual screening programmes were similar in effectiveness and costs.
CONCLUSION: To prevent ischaemic stroke associated with AF, both annual ECG screening and annual palpation screening were favourable in the context of conventional criteria for cost-effectiveness.

Entities:  

Mesh:

Year:  2004        PMID: 15153326     DOI: 10.1258/096914104774061092

Source DB:  PubMed          Journal:  J Med Screen        ISSN: 0969-1413            Impact factor:   2.136


  6 in total

1.  Diagnostic accuracy and yield of screening tests for atrial fibrillation in the family practice setting: a multicentre cohort study.

Authors:  F Russell Quinn; David J Gladstone; Noah M Ivers; Roopinder K Sandhu; Lisa Dolovich; Andrea Ling; Juliet Nakamya; Chinthanie Ramasundarahettige; Paul A Frydrych; Sam Henein; Ken Ng; Valerie Congdon; Richard V Birtwhistle; Richard Ward; Jeffrey S Healey
Journal:  CMAJ Open       Date:  2018-08-02

Review 2.  Systematic screening for the detection of atrial fibrillation.

Authors:  Patrick S Moran; Conor Teljeur; Mairin Ryan; Susan M Smith
Journal:  Cochrane Database Syst Rev       Date:  2016-06-03

3.  Stroke as the Initial Manifestation of Atrial Fibrillation: The Framingham Heart Study.

Authors:  Steven A Lubitz; Xiaoyan Yin; David D McManus; Lu-Chen Weng; Hugo J Aparicio; Allan J Walkey; Jose Rafael Romero; Carlos S Kase; Patrick T Ellinor; Philip A Wolf; Sudha Seshadri; Emelia J Benjamin
Journal:  Stroke       Date:  2017-01-12       Impact factor: 7.914

4.  Atrial Fibrillation Screening in Nonmetropolitan Areas Using a Telehealth Surveillance System With an Embedded Cloud-Computing Algorithm: Prospective Pilot Study.

Authors:  Juey-Jen Hwang; Yi-Lwun Ho; Ying-Hsien Chen; Chi-Sheng Hung; Ching-Chang Huang; Yu-Chien Hung
Journal:  JMIR Mhealth Uhealth       Date:  2017-09-26       Impact factor: 4.773

5.  Improving outpatient warfarin use for hospitalized patients with atrial fibrillation.

Authors:  Daniel R Touchette; Margaret E Mcguinness; Steve Stoner; David Shute; Jennifer M Edwards; Kathy Ketchum
Journal:  Pharm Pract (Granada)       Date:  2008-03-10

6.  Incremental yield of ECG screening repeated annually over 4 years in an adult Japanese population without prior atrial fibrillation: a retrospective cohort study.

Authors:  Yoshiki Nagata; Takashi Yamagami; Don Nutbeam; Ben Freedman; Nicole Lowres
Journal:  BMJ Open       Date:  2020-07-19       Impact factor: 2.692

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.